SDZ-AFL:一个生物类似的Aflibercept
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.
Clinical drug investigation
|July 24, 2025
概括
SDZ-AFL是一种aflibercept的生物类似药物,已在欧盟批准用于治疗神经血管与年龄相关的黄斑变性和其他视网膜疾病. 临床研究表明,与参考药物相等的疗效和类似的安全性.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 静脉内膜阿弗利塞普特是神经血管视网膜疾病的关键治疗方法.
- 生物类似药有可能增加获得有效治疗的机会.
研究的目的:
- 为了评估SDZ-AFL的疗效,安全性,耐受性和免疫性,这种生物类似的静脉内药物aflibercept.
- 将SDZ-AFL直接与新血管年龄相关黄斑变性 (nAMD) 患者的参考aflibercept进行比较.
主要方法:
- 在SDZ-AFL和参考aflibercept之间进行了物理化学和药理动力学性能比较.
- 在患有nAMD的患者中评估了药理动力学相似性.
- 在患有nAMD的患者群体中评估了临床疗效.
- 对耐受性,安全性和免疫性进行了监测.
主要成果:
- SDZ-AFL表现出与参考aflibercept类似的物理化学和药理动力学特性.
- 在患有nAMD的患者中证实了药理动力学相似性.
- 在患有nAMD的患者中,SDZ-AFL显示了相当于参考aflibercept的临床疗效.
- 耐受性,安全性和免疫性概况在SDZ-AFL和参考aflibercept之间是可比的.
结论:
- SDZ-AFL是用于眼科治疗的参考aflibercept的有效生物类似替代品.
- 该研究支持批准和使用SDZ-AFL用于已批准的指示,包括nAMD.
- SDZ-AFL提供了可比的治疗选择,具有类似的安全性和有效性.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K